Page last updated: 2024-10-23

benserazide and Syndrome

benserazide has been researched along with Syndrome in 8 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)."7.67Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984)
"A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)."3.67Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984)
"Psychotic features in patients with Parkinson's Disease usually present as visual hallucinations against a background of cognitive deterioration and dopaminomimetic therapy."1.36Isolated delusional syndrome in Parkinson's Disease. ( Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N, 2010)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19903 (37.50)18.7374
1990's3 (37.50)18.2507
2000's1 (12.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stefanis, N1
Bozi, M1
Christodoulou, C1
Douzenis, A1
Gasparinatos, G1
Stamboulis, E1
Stefanis, C1
Stefanis, L1
Lian, XF1
Luo, XD1
Zweije-Hofman, IL1
van der Zee, HJ1
van Nieuwenhuizen, O1
Trouillas, P1
Atchison, PR1
Thompson, PD1
Frackowiak, RS1
Marsden, CD1
Massarotti, G1
Cassi, E1
Passaleva, A1
De Keyser, J1
Herroelen, L1
Vervaeck, M1
Bruyland, M1
Ebinger, G1
Görke, W1
Bartholomé, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait[NCT01071590]45 participants (Actual)Observational2010-02-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for benserazide and Syndrome

ArticleYear
The syndrome of gait ignition failure: a report of six cases.
    Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:3

    Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gai

1993

Trials

2 trials available for benserazide and Syndrome

ArticleYear
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:9

    Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; D

2007
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
    Clinical neurology and neurosurgery, 1982, Volume: 84, Issue:2

    Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodop

1982

Other Studies

5 other studies available for benserazide and Syndrome

ArticleYear
Isolated delusional syndrome in Parkinson's Disease.
    Parkinsonism & related disorders, 2010, Volume: 16, Issue:8

    Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female;

2010
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
    Italian journal of neurological sciences, 1984, Volume: 5, Issue:3

    Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich

1984
Lupus-like autoimmune syndrome after levodopa and benserazide.
    British medical journal, 1979, Sep-01, Volume: 2, Issue:6189

    Topics: Autoimmune Diseases; Benserazide; Humans; Hydrazines; Levodopa; Lupus Erythematosus, Systemic; Male;

1979
Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism.
    Lancet (London, England), 1992, Jan-18, Volume: 339, Issue:8786

    Topics: Adult; Benserazide; Drug Combinations; Female; Hemiplegia; Humans; Levodopa; Parkinson Disease; Post

1992
Biochemical and neurophysiological investigations in two forms of Segawa's disease.
    Neuropediatrics, 1990, Volume: 21, Issue:1

    Topics: Adolescent; Basal Ganglia Diseases; Benserazide; Diagnosis, Differential; Dystonia; Evoked Potential

1990